Chemotherapy-induced peripheral neuropathy associated with phrenic paralysis: a case report
Keywords:
PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA, CHEMOTHERAPY, PARANEOPLASTIC POLYNEUROPATHY, PARALYSIS.Abstract
Introduction: chemotherapy-induced peripheral neuropathy is a side effect of cancer treatment that can cause loss of independence and impaired quality of life.
Objective: to describe a case of post-chemotherapy sensory-motor polyneuropathy that presented with respiratory failure secondary to phrenic paralysis.
Case presentation: a 10-year-old male patient presented with post-chemotherapy sensory-motor polyneuropathy associated with diaphragmatic paralysis. The patient had a history of acute lymphoblastic leukemia and was admitted to continue the treatment protocol. The patient presented with respiratory distress and ambulatory disorders. Electrophysiological examination revealed a predominantly axonal sensory-motor axo-myelinated polyneuropathy of moderate to severe intensity that affected most peripheral nerves, altering strength, trophism, and muscle tone, as well as the sensation of all four limbs. The patient progressed favorably, with recovery from neurological changes within a few weeks with the use of B vitamins and rehabilitation.
Conclusions: chemotherapy-induced peripheral neuropathy with phrenic paralysis is a rare neurological complication in children that requires appropriate evaluation and early detection to reduce or eliminate the resulting problems.
Downloads
References
1. Gómez Mercado CA, Segura Cardona AM, Pájaro Cantillo DE, Mesa Largo M. Incidencia y determinantes demográficos de la leucemia linfoide aguda en pacientes con cáncer pediátrico, Antioquia. Univ. Salud[Internet].2020 [citado 28/01/2022]; 22(2): 112-9. Disponible en: https://doi.org/10.22267/rus.202202.182
2. Querol Betancourt N, Chávez Isla MI, Leblanch Fernández CC, Jimenez Portuondo N. Caracterización clínico epidemiológica y supervivencia de pacientes menores de 19 años con leucemia. MEDISAN [Internet].2021 [citado 28/01/2022]; 25(1): 26. Disponible en: https://medisan.sld.cu/index.php/san/article/view/3303
3. Jiménez Morales S, Hidalgo Miranda A, Ramírez Bello J. Leucemia linfoblástica aguda infantil: una aproximación genómica Bol Med Hosp Infant Mex [Internet]. 2017 [citado 28/01/202]; 74(1):13-26. Disponible en: https://www.scielo.org.mx/pdf/bmim/v74n1/1665-1146-bmim-74-01-00013.pdf
4. Espinoza Diaz CI, Villacrés Peñafiel L, Caicedo Peñafiel G, Herrera Herrera M, Mayorga Gutierrez E, Cáceres Paredes AE et al. Leucemia linfoblastica aguda y complicaciones neurológicas en niños y adolescentes. Archivos Venezolanos de Farmacología y Terapéutica[Internet].2019 [citado 03/03/2022]; 38(6): 763-7.Disponible en: https://www.redalyc.org/journal/559/55964142016/55964142016.pdf
5. Machín García SA, Leblanch Fernández CC, García Caraballoso MB, Escalona Vives Y, Álvarez Molina I, Plá del Toro MJ, Valdés Sojo C. Caracterización de las leucemias en niños en Cuba (2006-2015). Rev Cubana de Hemat Inmunol Hemoter [Internet]. 2020 [citado 28/01/202]; 36(1): 1-15. Disponible en: https://revhematologia.sld.cu/index.php/hih/article/view/1103
6. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2021. Ministerio de Salud Pública de Cuba: La Habana [Internet];2022 [citado 24/01/2022]. Disponible en: https://instituciones.sld.cu/fatesa/files/2022/11/Anuario-Estad%C3%ADstico-de-Salud-2021.-Ed-2022.pdf
7. Martínez JW, Sánchez Naranjo JC, Londoño de los Ríos PA, Isaza Mejía CA. Prevalencia de neuropatía periférica asociada a quimioterapia en cuatro centros oncológicos de Colombia. Rev neurol [Internet].2019[citado 06/01/2022]; 69(3): 94-8 Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7039025
8. Martínez Pizarro S. Acupuntura en el tratamiento de los síntomas de la neuropatía periférica inducida por quimioterapia. Univ Méd Pinareña [Internet]. 2020 [citado 11/02/2022]; 16(2):1-3. Disponible en: https://revgaleno.sld.cu/index.php/ump/article/view/468
9. Quintana Castro C, Cirolini Oliveira C, Hörner R. Neuropatia periférica induzida por quimioterapia: uma revisão integrativa da literatura. Revista Saúde (Sta. Maria) [Internet]. 2021[citado 11/02/2022]; 47(1): 1-16 .Disponible en: https://periodicos.ufsm.br/revistasaude/article/view/65380/pdf
10. Vallejo M, Bermeo R, Knezevich A, Lino L. Manejo del dolor neuropático inducido por quimioterapia y radioterapia en un Servicio de Cuidados Paliativos. Rev. Oncol. Ecu [Internet]. 2017[citado 11/02/2022]; 27(1): 66-73.Disponible en: https://docs.bvsalud.org/biblioref/2019/06/998414/manejo-de-dolor-neuropatico.pdf
11. Expósito Vizcaíno SE, Casanova-Mollà J, Escoda L, Galán S, Miró J. Dolor neuropático en pacientes oncológicos en tratamiento con bortezomib. Neurología [Internet]. 2018[citado 11/02/2022]; 33(1): 28-34.Disponible en: https://doi.org/10.1016/j.nrl.2016.05.008
12. Contreras I, Escobar R, Necochea C, Castro S, Sánchez I. Tres casos de parálisis diafragmática: Utilidad del estudio electromiográfico. Rev. chil. pediatr [Internet]. 2004 [citado 03/03/2022]; 75(1): 48-54. Disponible en: http://dx.doi.org/10.4067/S0370-41062004000100007
13. Gómez Tejada RA, Rolando LM. Parálisis diafragmática unilateral: diagnóstico y evaluación de la función muscular. Serie de nueve casos. Respirar [Internet]. 2017[citado 03/03/2022]; 9(2): 11-15. Disponible en: https://alatorax.org/es/publicaciones/respirar/21/8/download/8_file_es_EHIStw_respirar-alat-vol9num2ago2017-web-11a15.pdf.
14. Kokatnur L, Rudrappa M. Diaphragmatic Palsy. Diseases [Internet]. 2018[citado 03/03/2022]; 6(16):1-14. Disponible en: https://doi.org/10.3390/diseases6010016
15. Amato AA, Barohn RJ. Capitulo 438. Neuropatía periférica. En: Jameson L, Fauci AS, Kasper D, Hauser SL, Longo DL, Loscalzo J. Harrison Principios de Medicina Interna. 20a edición. Editoral McGraw-Hill Education: México[Internet]; 2018 [citado 03/03/2022]: 3204-3217. Disponible en: https://dialnet.unirioja.es/servlet/libro?codigo=828623
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jorge Luis Hernández Gonzalez.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
